WATCH: How can we ensure patients access innovative medicines quickly?
What can the UK Government and others do to ensure the system keeps pace with scientific developments, helping patients overcome delays in accessing innovative new medicines?
Over recent decades, programmes such as the Early Access to Medicines Scheme and Accelerated Access Collaborative alongside the Cancer Drug Fund have pushed forward initiatives to improve access to medicines.
However, these changes have been introduced gradually and there has been a disconnect in how they interact resulting in a regulatory and access environment for medicines which is complex and confusing, often resulting in delays for patients in accessing new innovations.
Dods and Abbvie gathered a panel of experts – including Innovation Minister Lord Bethall – to discuss how government and industry can work together to ensure the best health technologies get into the hands of the patients who need them.
- Lord Bethell, Minister for Innovation
- Chris Green MP, Chair of the Medical Research APPG and contributor to the Bridging the Gap report (Chair)
- Zack Pemberton-Whiteley, Chair, Blood Cancer Alliance
- Dominic Pivonka, Director of Market Access, AbbVie
Prepared January 2021
Get the inside track on what MPs and Peers are talking about. Sign up to The House's morning email for the latest insight and reaction from Parliamentarians, policy-makers and organisations.